IFX-101 Investigational IL-22 antibody for moderate-to-severe atopic dermatitis, in manufacturing development ahead of planned first-in-human studies in 2027.
Visit productCosigns Received
Be the first Cosign
Put your name behind IFX-101.
Add it to your Products I use list and share why you use it.